Seaport Global Securities Begins Coverage on Redhill Biopharma Ltd. (NASDAQ:RDHL)

Analysts at Seaport Global Securities started coverage on shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) in a report released on Friday, October 6th, Marketbeat.com reports. The firm set a “buy” rating and a $19.00 price target on the biotechnology company’s stock. Seaport Global Securities’ target price suggests a potential upside of 118.14% from the company’s previous close.

Other equities analysts have also recently issued research reports about the company. Zacks Investment Research cut Redhill Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, July 29th. Roth Capital set a $27.00 price objective on Redhill Biopharma and gave the company a “buy” rating in a report on Monday, July 31st. FBR & Co restated a “buy” rating on shares of Redhill Biopharma in a report on Friday, June 16th. HC Wainwright set a $33.00 target price on shares of Redhill Biopharma and gave the company a “buy” rating in a research note on Thursday, June 15th. Finally, UBS AG started coverage on shares of Redhill Biopharma in a research note on Wednesday, September 13th. They issued a “reduce” rating for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $23.35.

Shares of Redhill Biopharma (RDHL) opened at 8.71 on Friday. The stock has a 50 day moving average price of $9.05 and a 200-day moving average price of $9.26. Redhill Biopharma has a 1-year low of $8.16 and a 1-year high of $14.22. The company’s market cap is $149.49 million.

Redhill Biopharma (NASDAQ:RDHL) last posted its quarterly earnings results on Tuesday, July 25th. The biotechnology company reported ($0.60) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.02). The firm had revenue of $0.48 million during the quarter, compared to the consensus estimate of $0.34 million. Analysts predict that Redhill Biopharma will post ($2.39) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://ledgergazette.com/2017/10/19/redhill-biopharma-ltd-rdhl-research-coverage-started-at-seaport-global-securities.html.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC lifted its holdings in shares of Redhill Biopharma by 144.1% during the first quarter. Renaissance Technologies LLC now owns 62,000 shares of the biotechnology company’s stock worth $595,000 after purchasing an additional 36,600 shares during the period. D.A. Davidson & CO. lifted its holdings in Redhill Biopharma by 10.0% in the second quarter. D.A. Davidson & CO. now owns 44,000 shares of the biotechnology company’s stock valued at $379,000 after buying an additional 4,000 shares during the period. Jane Street Group LLC acquired a new position in shares of Redhill Biopharma during the first quarter valued at about $276,000. Family Management Corp raised its holdings in shares of Redhill Biopharma by 51.5% during the second quarter. Family Management Corp now owns 25,750 shares of the biotechnology company’s stock valued at $222,000 after purchasing an additional 8,750 shares during the period. Finally, Oppenheimer & Co. Inc. raised its holdings in shares of Redhill Biopharma by 10.8% during the seco

Other equities analysts have also recently issued research reports about the company. Zacks Investment Research cut Redhill Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, July 29th. Roth Capital set a $27.00 price objective on Redhill Biopharma and gave the company a “buy” rating in a report on Monday, July 31st. FBR & Co restated a “buy” rating on shares of Redhill Biopharma in a report on Friday, June 16th. HC Wainwright set a $33.00 target price on shares of Redhill Biopharma and gave the company a “buy” rating in a research note on Thursday, June 15th. Finally, UBS AG started coverage on shares of Redhill Biopharma in a research note on Wednesday, September 13th. They issued a “reduce” rating for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $23.35.

Shares of Redhill Biopharma (RDHL) opened at 8.71 on Friday. The stock has a 50 day moving average price of $9.05 and a 200-day moving average price of $9.26. Redhill Biopharma has a 1-year low of $8.16 and a 1-year high of $14.22. The company’s market cap is $149.49 million.

Redhill Biopharma (NASDAQ:RDHL) last posted its quarterly earnings results on Tuesday, July 25th. The biotechnology company reported ($0.60) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.02). The firm had revenue of $0.48 million during the quarter, compared to the consensus estimate of $0.34 million. Analysts predict that Redhill Biopharma will post ($2.39) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://ledgergazette.com/2017/10/19/redhill-biopharma-ltd-rdhl-research-coverage-started-at-seaport-global-securities.html.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC lifted its holdings in shares of Redhill Biopharma by 144.1% during the first quarter. Renaissance Technologies LLC now owns 62,000 shares of the biotechnology company’s stock worth $595,000 after purchasing an additional 36,600 shares during the period. D.A. Davidson & CO. lifted its holdings in Redhill Biopharma by 10.0% in the second quarter. D.A. Davidson & CO. now owns 44,000 shares of the biotechnology company’s stock valued at $379,000 after buying an additional 4,000 shares during the period. Jane Street Group LLC acquired a new position in shares of Redhill Biopharma during the first quarter valued at about $276,000. Family Management Corp raised its holdings in shares of Redhill Biopharma by 51.5% during the second quarter. Family Management Corp now owns 25,750 shares of the biotechnology company’s stock valued at $222,000 after purchasing an additional 8,750 shares during the period. Finally, Oppenheimer & Co. Inc. raised its holdings in shares of Redhill Biopharma by 10.8% during the second quarter. Oppenheimer & Co. Inc. now owns 25,569 shares of the biotechnology company’s stock valued at $220,000 after purchasing an additional 2,500 shares during the period. 10.99% of the stock is currently owned by hedge funds and other institutional investors.

Redhill Biopharma Company Profile

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply